

SECURITY CLASSIFICATION

AD-A200 051

Form Approved
OMB No 0704-0188
Exp Date Jun 30, 1986

1a REPORT SECURITY

UNCLASSIFIED

2a SECURITY CLASSIFICATION AUTHORITY

UNCLASSIFIED

2b DECLASSIFICATION/DOWNGRADING SCHEDULE

UNCLASSIFIED

4 PERFORMING ORGANIZATION REPORT NUMBER(S)

3 DISTRIBUTION/AVAILABILITY OF REPORT

5 MONITORING ORGANIZATION REPORT NUMBER(S)

6a NAME OF PERFORMING ORGANIZATION

Dept of Hematology & Div of
Pathology, WRAIR6b. OFFICE SYMBOL
(if applicable)

7a NAME OF MONITORING ORGANIZATION

WRAIR

6c. ADDRESS (City, State, and ZIP Code)

Washington, DC 20307-5100

7b. ADDRESS (City, State, and ZIP Code)

Washington, DC 20307-5100

8a NAME OF FUNDING/SPONSORING
ORGANIZATION

Ft. Detrick, Frederick, Md

8b. OFFICE SYMBOL
(if applicable)

9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER

8c. ADDRESS (City, State, and ZIP Code)

US ARMY MED RSCH & DEV COMMAND
Ft. Detrick, Frederick, MD 21701-5012

10. SOURCE OF FUNDING NUMBERS

PROGRAM
ELEMENT NO.PROJECT
NO.TASK
NO.WORK UNIT
ACCESSION NO.

11 TITLE (Include Security Classification)

Plasminogen Activator Inhibitor: A Regulator of Ancrod-Induced Fibrin
Deposition in Rabbits

12 PERSONAL AUTHOR(S)

C.KRISHNAMURTI, C.F.BARR, M ALYCIA HASSET, G.D. YOUNG, AND B.M. ALVING

13a TYPE OF REPORT

MANUSCRIPT

13b. TIME COVERED

FROM _____ TO _____

14. DATE OF REPORT (Year, Month, Day)

15. PAGE COUNT

6

16 SUPPLEMENTARY NOTATION

17 COSATI CODES

FIELD

GROUP

SUB-GROUP

18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)

19 ABSTRACT (Continue on reverse if necessary and identify by block number)

DTIC
ELECTE
S OCT 07 1988 D
E

20 DISTRIBUTION/AVAILABILITY OF ABSTRACT

☒ UNCLASSIFIED/UNLIMITED ☐ SAME AS RPT ☐ DTIC USERS

21 ABSTRACT SECURITY CLASSIFICATION

UNCLASSIFIED

22a NAME OF RESPONSIBLE INDIVIDUAL

Chitro Krishnamurti

22b TELEPHONE (Include Area Code)

22c OFFICE SYMBOL

DD FORM 1473, 84 MAR

83 APR edition may be used until exhausted
All other editions are obsolete

SECURITY CLASSIFICATION OF THIS PAGE

88 10 6 066

UNCLASSIFIED

Plasminogen Activator Inhibitor: A Regulator of Ancrod-Induced Fibrin Deposition in Rabbits

By Chitra Krishnamurti, Charles F. Barr, M. Alycia Hassett, G. David Young, and Barbara M. Alving

Plasma levels of a fast-acting plasminogen activator inhibitor (PAI), which neutralizes both tissue plasminogen activator (t-PA) and urokinase, are markedly increased in endotoxin-treated rabbits. The ability of this inhibitor to prevent the fibrinolysis that occurs after a thrombogenic stimulus was investigated in a rabbit model. Normal and endotoxin-treated male New Zealand rabbits were infused with ancrod, an enzyme that causes noncrosslinked fibrin formation *in vivo*. Ancrod stimulated t-PA activity by 90% in normal rabbits and caused hypofibrinogenemia but did not increase PAI levels or induce fibrin deposition in target organs. Rabbits injected with endotoxin (10 µg/kg)

showed an increase in PAI from 1 to 32 U/mL 4 hours later. When ancrod was infused at this time, 90% of the rabbits developed renal fibrin thrombi. Fibrin deposition was recorded in 40% of the rabbits that received a lower dose of endotoxin (1.0 µg/kg) and had a PAI level of 14 U/mL at the time of ancrod infusion 4 hours later. Fibrin deposition did not occur in the endotoxin-treated rabbits that received normal saline. These data suggest that high levels of PAI inhibit fibrinolysis *in vivo*, thereby promoting fibrin clot deposition following a thrombogenic stimulus.

This is a US Government work. There are no restrictions on its use.

TWO CRITICAL FACTORS in the regulation of fibrinolysis *in vivo* are the functional levels of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI), both of which are identical to those produced by endothelial cells.¹⁻³ PAI, a 50,000-mol-wt protein, has an apparent half-life ($t_{1/2}$) of 7 minutes when measured in the rabbit circulation⁴ and is the major inhibitor of t-PA and urokinase in both humans⁵ and rabbits.^{4,6} Elevated levels of PAI have been found in plasma from patients who have had venous thromboses,^{7,8} gram-negative sepsis,^{4,9} and many other conditions predisposing to fibrin clot formation.¹⁰

Colucci and co-workers⁴ demonstrated that infusion of endotoxin into rabbits increases PAI levels in a dose-dependent manner; they postulated that high levels of this inhibitor may have a physiologic role in the coagulopathy associated with endotoxemia. Although other investigators showed that infusion of soluble fibrin into endotoxin-treated rabbits results in renal microclot formation,¹¹ whether the apparent inhibition of fibrinolysis by endotoxin is mediated through its ability to increase levels of circulating PAI is not known.

The present study used endotoxin-treated rabbits to determine if elevated PAI levels could inhibit the fibrinolysis that occurs after infusion of ancrod, an enzyme that induces non-crosslinked fibrin clots by cleaving fibrinopeptides A, AP, and AY.¹²⁻¹⁴ Ancrod causes hypofibrinogenemia and elevated titers of fibrinogen-fibrin degradation products (FDP-fdp) when infused slowly into rabbits and humans.^{15,16}

This study demonstrates that ancrod does not cause fibrin deposition in normal rabbits, presumably because of the

fibrinolysis that occurs in response to its initial coagulant action. Ancrod can, however, induce fibrin deposition in animals that have elevated levels of PAI. The data indicate that PAI may promote fibrin formation by preventing the endogenous fibrinolysis that occurs after a thrombogenic stimulus.

MATERIALS AND METHODS

Materials. Purified two-chain human t-PA was purchased from American Diagnostica, Greenwich, CT. The specific activity was 100,000 U/mg, as determined with an international urokinase standard; the data in this article are expressed in terms of this standard. If this preparation of t-PA were calibrated against the International Reference Preparation for t-PA,¹⁷ the specific activity would be ~500,000 IU/mg.¹⁸ Urokinase (specific activity, 100,000 U/mg) was purchased from Abbott Laboratories, North Chicago. Human fibrinogen and Cohn fraction III paste were obtained from Cutter Laboratories, Berkeley, CA. Plasminogen was purified from the paste by affinity chromatography¹⁹ on lysine-Sepharose (Pharmacia Fine Chemicals, Uppsala, Sweden); the specific activity was 20 CTA U/mg. Human thrombin (H-2) and human plasmin (7.3 U/mg) were supplied by the Office of Biologics, Bethesda, MD. The synthetic substrate D-Val-Leu-Lys-pNA (S-2251) was purchased from Kabi Diagnostica, Stockholm. Ancrod, an enzyme derived from the Malayan pit viper, was the generous gift of Knoll Pharmaceutical, Whippany, NJ, and endotoxin (*Escherichia coli* 0111:B4) was purchased from Difco Laboratories, Detroit.

Animal experiments. Male New Zealand white rabbits weighing between 2.3 and 3.5 kg were received from a single supplier at least 1 week before use and were given standard laboratory food and water *ad libitum*. Endotoxin was infused into a marginal ear vein during 5 minutes in a total volume of 3 mL of normal saline at a dose of 1.0 or 10.0 µg/kg. Ancrod (2 U/kg) was administered by an infusion pump in a total volume of 20 mL of normal saline into a marginal ear vein during 1 hour. The vasopressin analogue 1-desamino-8-D-arginine vasopressin (DDAVP, Armour Pharmaceutical, Kankakee, IL) was infused into a marginal ear vein during 10 minutes at a dose of 0.4 µg/kg in 10 mL of normal saline. Blood samples (0.9 mL) were collected from the uninfused marginal ear vein into polypropylene tubes that contained 0.1 mL of 2% EDTA and immediately centrifuged for 1 minute at 22 °C in an Eppendorf centrifuge 3200 (Brinkman Instruments, Westbury, NY). The plasma was immediately separated from the RBCs, and aliquots were stored at -70 °C or acidified in preparation for measurement of plasminogen activator.

Assay of plasminogen activator activity. Assay for plasminogen activator activity was performed according to the method of Wiman

From the Department of Hematology and the Division of Pathology, Walter Reed Army Institute of Research, Washington, DC.

Submitted August 4, 1986; accepted October 1, 1986.

Address reprint requests to Dr Chitra Krishnamurti, Department of Hematology, Walter Reed Army Institute of Research, Washington, DC 20307-5100.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

This is a US Government work. There are no restrictions on its use.

0006-4971/87/6903-0015\$0.00/0

and colleagues.²⁰ Plasma was acidified with an equal volume of 1.0 mol/L of sodium acetate pH 3.9 and incubated at 22 °C for 15 minutes. An aliquot of this mixture was diluted to a final plasma concentration of 0.5% in 0.05 mol/L of Tris, 0.1 mol/L NaCl, and 0.1% Triton X-100 pH 8.8 (NEN, Boston), and incubated with 1 mmol/L of S-2251 and 0.3 mg/mL of plasminogen in the presence of fibrin (70 µg/mL) for 6 hours at 37 °C in a microtiter plate. The change in absorbance was measured at 405 nm with a Titertek Multiscan Spectrophotometer (Flow Lab, McLean, VA).

Assay of PAI activity. The PAI assay was performed as described by Chmielewska and colleagues.²¹ Human t-PA (10 µL, 2 U/mL final) was incubated for 10 minutes at 22 °C with 40 µL of plasma that was undiluted or diluted in 0.02 mol/L of sodium phosphate, 0.1 mol/L of NaCl pH 7.3. Residual t-PA activity was measured after acidification and dilution of the sample as described previously. One unit of inhibitor is defined as the amount that inactivates 1 U of t-PA during the 10-minute incubation period.

Assay of plasmin-inhibitor activity. Plasmin (final concentration 0.6 CTA U/mL) was incubated for 20 seconds at 30 °C with rabbit plasmas diluted 1/20 and 3/40 in 0.05 mol/L of Tris and 0.15 mol/L of NaCl pH 7.4. After 20 seconds, a 30-µL sample was added to 1 mL of 0.1 mmol/L of S-2251 in 0.05 mol/L of Tris pH 7.4, and the change in absorbance at 405 nm was monitored with a Cary recording spectrophotometer (Varian Associates, Instrument Division, Palo Alto, CA). The results were expressed as the percentage of activity of a standard of pooled human plasma.

Plasma plasminogen assay. Plasma was mixed with an equal volume of 1.0 mol/L of sodium acetate pH 3.9 and diluted to final concentrations of 2% and 1% with 0.05 mol/L of Tris, 0.1 mol/L of lysine, and 0.1% human albumin, pH 7.4. A 200-µL mixture containing 0.05% to 2.5% plasma, urokinase (2,500 U), S-2251 (0.2 mmol/L) in Tris-lysine buffer was then incubated in a microtiter plate for 30 minutes at 22 °C, and the change in absorbance was compared with that obtained with a standard curve prepared from human plasmin of known activity.

Fibrin plate zymography. Plasma samples were electrophoresed in sodium dodecyl sulfate (SDS) on an 8% polyacrylamide gel that was then washed for 30 minutes in 0.1 mol/L of Tris pH 8 containing 0.1% Triton X-100.²² The gel was overlaid with a fibrin monolayer containing plasminogen, incubated at 37 °C for 16 hours, and photographed.²²

Fibrinogen and FDP-fdp. The fibrinogen concentration was determined spectrophotometrically after plasma was clotted with a calcium-thrombin solution for 1 hour, and the clot was washed with normal saline followed by solubilization in alkaline urea.¹⁵ The FDP-fdp were measured in a tanned RBC hemagglutination immunoassay that was modified for use in rabbits.¹⁵

Data analysis. The results of experiments were expressed as the mean ± SEM. Statistical analysis was performed with a Student's *t* test on paired samples.

Table 1. Measurement of PA Activity in Rabbit Plasma

Rabbit No.	PA (U/mL)		
	A	B	C
I	0.41	0.42	0.09
II	0.66	0.66	0.42
III	0.55	0.51	0.23
IV	0.74	0.60	0.34
Mean ± SEM	0.59 ± 0.07	0.55 ± 0.05	0.27 ± 0.07

Plasma was acidified, diluted to 0.5%, and assayed immediately (A); acidified, diluted, frozen at -70 °C for 24 hours and then thawed and assayed (B); acidified, frozen at -70 °C for 24 hours and then diluted and assayed (C).

Histopathology. Necropsies were performed on animals that died during anecrod infusion or were killed by a 5-mL intravenous (IV) injection of sodium pentobarbital (V-Pento C, 65 mg/mL) 1 hour after completion of the infusion. Within 20 minutes of death, tissues from all animals were immersion-fixed in neutral buffered 10% formalin, processed, embedded in paraffin, and stained with hematoxylin and eosin. Sections of lung, liver, kidney, and spleen were also stained with phosphotungstic acid hematoxylin (PTAH)²³ and examined for the presence of fibrin microthrombi by a pathologist who was unaware of the experimental protocol for the individual animals.

RESULTS

Measurement and characterization of PA in rabbit plasma. Although freezing acidified human plasma has been reported not to affect the PA activity,²⁰ freezing and storage of rabbit plasma at -70 °C caused a significant decrease in PA activity as compared with that of unfrozen samples (Table 1). When acidified rabbit plasma was diluted to a final plasma concentration of 0.5% in Triton X-100 buffer and then stored at -70 °C, the PA remained unchanged from that measured in fresh plasma. Therefore, all plasmas were stored at -70 °C after acidification and dilution in Triton X-100 buffer. The apparent lability of rabbit PA could not be explained on the basis of qualitative or quantitative alterations in activators or inhibitors. Both species have similar levels of PAI and PA⁶; by fibrin zymography, the mol wt of PA in rabbit plasma is 68,000, similar to that of human t-PA.⁶ The PAI in rabbit plasma has the same mol wt as the PAI that has been characterized in human plasma.⁴

Effects of anecrod infusion in normal rabbits. When anecrod was infused into normal rabbits, fibrinogen levels decreased from 2.2 ± 0.1 to 0.3 ± 0.1 g/L and FDP-fdp increased from a baseline titer of 1/32 to 1/4098 at 1.5 hours after initiation of the infusion. These alterations were associated with a significant increase in PA activity of $91.3\% \pm 16.1\%$ ($P < .01$, Fig 1). Six hours later, the PA levels had returned to baseline values, and the fibrinogen levels were still depressed (0.4 g/L). When anecrod was infused at this time into these hypofibrinogenemic rabbits, PA activity was again increased by $40.7\% \pm 14.6\%$ above the 6-hour value




Fig 1. Effect of anecrod on plasminogen activator (PA) activity in hypofibrinogenemic rabbits. Anecrod (2 U/kg) was infused at 0 and 6 hours. PA activity (—) and fibrinogen levels (---) were determined at the indicated time points. Data are the mean ± SEM of four rabbits.




Fig 2. Fibrin zymogram of paired rabbit plasmas obtained before and 1.5 hours after infusion of ancrod or saline. Samples were electrophoresed in sodium dodecyl sulfate (SDS) on an 8% polyacrylamide gel. Lanes 1,3, pre-ancrod samples, lanes 2,4, post-ancrod; lanes 5,7, pre-saline; lanes 6,8, post-saline; lane 9, human-melanoma tissue plasminogen activator (t-PA); lane 10, human urokinase.

($P < .05$) and fibrinogen levels became undetectable. The PA values remained elevated for another 2 hours after the second ancrod infusion. By fibrin plate zymography, the PA before and after ancrod was 68,000 mol wt (Fig 2), suggesting that the increase in PA after ancrod was t-PA. Ancrod had no effect on PAI levels, which were <1 U/mL when measured before and at 1.5 hours after infusion. Infusions of saline into six control rabbits caused no increase in PA, PAI, or change in fibrinogen levels (data not shown).

To determine if ancrod could stimulate release of PA in the absence of any detectable fibrinogen, a group of animals was rendered afibrinogenemic by infusing ancrod at 0 to 1 hour and again at 2 to 3 hours (Fig 3). At 6 hours, these afibrinogenemic rabbits received either a third infusion of ancrod or DDAVP, which is known to stimulate PA in normal rabbits by 40%.⁶ Ancrod caused no increase in PA when infused at this time; however, PA was significantly increased by 26% ($P < .05$) in the five rabbits that had received DDAVP. These data indicate that ancrod stimulates PA release only when infused into rabbits that have circulating fibrinogen, suggesting that clot formation induced by ancrod is the stimulus for PA release. The ability of the afibrinogenemic rabbits to release PA when infused with DDAVP indicates that the PA stores had not been completely depleted by two previous infusions of ancrod.

Ancrod-induced fibrin deposition in endotoxin-treated rabbits. Infusion of endotoxin into rabbits caused a dose-dependent increase in both PA and PAI (Fig 4A and B). One group of rabbits received endotoxin at a dose of 1 μ g/kg, followed by an infusion of normal saline or ancrod 4 hours later (Fig 4A). Approximately 90 minutes after endotoxin infusion, PA was maximally increased by $41.2\% \pm 10.5\%$ above baseline values ($P < .01$), returning to normal values by 4 hours. PAI levels increased from <1 U/mL to maximum values of 14.3 ± 2.3 U/mL at 4 hours. Infusion of ancrod at this time did not cause an increase in PA, although fibrinogen levels decreased from 1.7 ± 0.3 to 0.1 ± 0.1 g/L. At necropsy, 40% of the rabbits had evidence of renal thrombi (Table 2). One of these animals also had pulmonary thrombi. None of the endotoxin-treated animals that received saline instead of ancrod showed any evidence of fibrin deposition.

A second group of rabbits was infused with endotoxin at a dose of 10 μ g/kg, followed by ancrod or normal saline 4 hours later. After infusion of endotoxin, PA was maximal at

30 minutes and declined at 90 minutes as PAI levels rapidly increased (Fig 4B). By 4 hours, PAI had increased from <1 to 32 U/mL; plasminogen levels had decreased from 5.9 to 4.2 U/mL, and α_2 -antiplasmin was decreased by 36%. Thus the most striking change in components of the fibrinolytic system 4 hours after this dose of endotoxin was the marked increase in PAI. Infusion of ancrod at this time caused glomerular fibrin deposition in 90% of the animals (Table 2). One of these animals also had pulmonary thrombi, and one demonstrated pulmonary and splenic thrombi in addition to the fibrin deposition in the glomeruli (Fig 5). The endotoxin-treated animals that received saline had no demonstrable fibrin deposition.

These data suggested that endotoxin, by increasing PAI levels, promoted fibrin deposition in the ancrod-treated rabbits. The following experiment was done to determine if ancrod induced clot deposition when infused into endotoxin-treated rabbits that had PAI levels <1 U/mL at the time of initiation of infusion. Ancrod was infused into rabbits 30 minutes after they had received endotoxin (10 μ g/kg). PAI levels increased from <1 to ~ 16 U/mL during the ancrod infusion and were 24 U/mL 1 hour later, at the time of necropsy. Fibrin deposition was detected in 50% of these rabbits (Table 2).

All rabbits infused with ancrod alone or with endotoxin at a dose of 1.0 μ g/kg followed by ancrod survived the infusion.





Fig 3. Fibrinolytic response in rabbits after multiple infusions of ancrod. Plasminogen activator (PA) activity (—) and fibrinogen levels (---) were measured at the indicated time intervals after ancrod infusions at 0, 2 and 6 hours. Results are the mean $\pm$ SEM of five rabbits.

Fig 4. Effect of anacrod on endotoxin-treated rabbits. Endotoxin was administered at doses of 1 $\mu\text{g}/\text{kg}$ (A, 12 rabbits) or 10 $\mu\text{g}/\text{kg}$ (B, 13 rabbits), and anacrod was infused 4 hours later. The plasminogen activator (PA) (—) and PA inhibitor (PAI) (---) activities (mean $\pm$ SEM) are shown.



Animals that received endotoxin at the higher dose of 10 $\mu\text{g}/\text{kg}$ followed by anacrod at 30 minutes or 4 hours had mortalities of 50% and 40%, respectively. The mortality was 14% for those animals that received only saline 4 hours after this dose of endotoxin. Mortality could not be correlated with the presence of fibrin deposition.

DISCUSSION

The present study demonstrates that when a thrombogenic stimulus such as anacrod is infused slowly into normal rabbits, PA levels increase as a result of the coagulant action of anacrod on fibrinogen. PAI levels are not increased and fibrin deposition does not occur after anacrod infusion alone. However, rabbits that have a high level of PAI at the initiation of anacrod administration or rabbits that are undergoing rapid increases in PAI during the infusion may develop fibrin

deposition, predominantly in the glomeruli. It is unlikely that alterations in other components of the fibrinolytic system are sufficient to be implicated in the thrombus formation that occurred in endotoxin-treated rabbits that received anacrod. Although plasminogen levels decreased after endotoxin infusion, α_2 -antiplasmin levels were lower as well.

The infusion of endotoxin also causes leukopenia, generation of cellular and humoral procoagulant activity, and activation of the complement system.²⁴ These alterations, however, do not appear to be significant factors in the induction of fibrin formation described in the present study. In their work with rabbits deficient in the sixth component of complement, Muller-Berghaus and Lohmann demonstrated that the complement system does not have a role in the induction of renal microclot formation in animals that receive a continuous infusion of endotoxin.²⁵ Muller-Berghaus and coworkers also reported that rabbits injected simultaneously with anacrod and endotoxin developed glomerular microclots that could not be prevented by heparin²⁶ or by first rendering the animals neutropenic with nitrogen mustard.²⁷ They concluded that the endotoxin-mediated generation of

Table 2. Summary of Histologic Studies

Study/Treatment	Fibrin Thrombi		PAI Levels (U/mL)* (Mean $\pm$ SEM)
	(%)	(No. of Animals)	
Experimental			
Endotoxin (1 $\mu\text{g/kg}$), ancrod (4 h)†	40%	(2/5)†	11.7 $\pm$ 3.1
Endotoxin (10 $\mu\text{g/kg}$), ancrod (4 h)	90%	(9/10)	33.3 $\pm$ 3.4
Endotoxin (10 $\mu\text{g/kg}$), ancrod (30 min)	50%	(3/6)	0.2 $\pm$ 0.1
			24.7 $\pm$ 3.4
Controls			
Endotoxin (1 $\mu\text{g/kg}$), saline (4 h)	0%	(0/4)	20.4 $\pm$ 6.0
Endotoxin (10 $\mu\text{g/kg}$), saline (4 h)	0%	(0/7)	33.3 $\pm$ 2.9
Saline, ancrod (4 h)	0%	(0/4)	2.0 $\pm$ 1.6

*Plasminogen activator inhibitor (PAI) levels at time of second infusion (anacrod or saline). For rabbits that received anacrod 30 minutes after endotoxin, PAI levels had not yet reached a plateau and increased from 0.2 to 24.7 U/mL at time of necropsy.

†Time of second infusion (anacrod or saline). After the administration of endotoxin, anacrod or saline was infused into the animals. Survivors were killed 1 hour postinfusion. Lung, liver, spleen, and kidneys were fixed, stained with phosphotungstic acid hematoxylin (PTAH), and examined for the presence of fibrin microthrombi.




Fig 5. Histopathologic evidence of fibrin microthrombi (dark, fibrillar areas) in the glomeruli of a rabbit infused with endotoxin (10 $\mu\text{g}/\text{kg}$) and then anacrod 4 hours later. The animal was killed 1 hour after completion of anacrod infusion.

microclots in anerod-infused rabbits did not involve neutrophils or the generation of procoagulant activity by endotoxin.

Additional indirect evidence for the role of PAI in inhibiting fibrinolysis is suggested by the studies of Szczepanski and Lucier,²⁸ who reported that the infusion of a single dose of endotoxin into rabbits caused an increase in the fibrinolytic activity of the plasma euglobulin fraction within the first hour, followed by a decrease in the plasminogen activator activity of kidney tissue at ~6 hours. Bergstein and Michael²⁹ found that fibrinolytic activity was present in the renal cortices of rabbits killed 30 minutes after a single dose of endotoxin but was undetectable in animals killed from 1 to 24 hours later. The activity reappeared at 24 hours, thus following a time course consistent with induction of PAI. The loss of fibrinolytic activity after infusion of endotoxin alone was not associated with fibrin deposition.

The vulnerability of the kidneys of the endotoxin-treated rabbits to fibrin deposition after anerod may reflect the low level of PA activity relative to the levels of PAI within this particular organ. In the present study, only 3 of 14 rabbits that developed renal fibrin deposition had pulmonary thrombi as well. One explanation for these findings is that

pulmonary tissue can have an inhibitory effect on the function of PAI, as was recently demonstrated by Colucci and co-workers.¹⁸ These investigators showed that addition of rabbit lung slices to a whole blood clot markedly enhanced its lysis when it was incubated in the presence of PAI inhibitor-rich plasma *in vitro*.

The highest levels of PAI appear to be induced by endotoxin in humans^{4,9} as well as in rabbits. However, the levels of PAI required to prevent fibrinolysis are not known for specific clinical settings. The levels may depend on the type of thrombogenic stimulus that is acting in a given situation. For example, anerod induces non-crosslinked fibrin formation which undergoes lysis relatively easily. The generation of small amounts of thrombin which causes activation of coagulation factor XIII with crosslinking of α_2 -antiplasmin to the clot³⁰ may be much more thrombogenic and require larger concentrations of activator for lysis.

Elevated PAI levels appear to be a significant factor for clot formation when a thrombogenic stimulus such as anerod is administered. Monitoring levels of this inhibitor in patients, especially those in sepsis, may allow prevention of renal fibrin deposition, which is not uncommon in this clinical condition.³¹

REFERENCES

1. Loskutoff DJ, Edgington TS: Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. *Proc Natl Acad Sci* 74:3903, 1977
2. Loskutoff DJ, Mussoni L: Interactions between fibrin and the plasminogen activators produced by cultured endothelial cells. *Blood* 62:62, 1983
3. Erickson LA, Hekman CM, Loskutoff DJ: The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. *Proc Natl Acad Sci* 82:8710, 1985
4. Colucci M, Paramo JA, Collen D: Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. *J Clin Invest* 75:818, 1985
5. Kruithof EKO, Tran-Thang C, Bachmann F: The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase. *Thromb Haemostas* 55:65, 1986
6. Hassett MA, Krishnamurti C, Barr CF, Alving BM: The rabbit as a model for studies of fibrinolysis. *Thromb Res* 43:313, 1986
7. Wiman B, Ljungberg B, Chmielewska J, Urden G, Blomback M, Johnsson H: The role of the fibrinolytic system in deep vein thrombosis. *J Lab Clin Med* 105:265, 1985
8. Haggroth L, Mattsson C, Felding P, Nilsson IM: Plasminogen activator inhibitors in plasma and platelets from patients with recurrent venous thrombosis and pregnant women. *Thromb Res* 42:585, 1986
9. Engebretsen LF, Kierulf P, Brandtzaeg P: Extreme plasminogen activator inhibitor and endotoxin values in patients with meningococcal disease. *Thromb Res* 42:713, 1986
10. Juhan-Vague I, Moerman B, DeCock F, Aillaud MF, Collen D: Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. *Thromb Res* 33:523, 1984
11. Hofmann H, Mahn I, Muller-Berghaus G: The generation of microclots from circulating soluble des-A fibrin. *Thromb Haemostas* 42:39A, 1979 (abstr)
12. Ewart MR, Hatton MWC, Basford JM, Dodgson KS: The proteolytic action of Arvin on human fibrinogen. *Biochem J* 118:603, 1970
13. Holleman WH, Coen LJ: Characterization of peptides released from human fibrinogen by Arvin. *Biochim Biophys Acta* 200:587, 1970
14. Pizzo SV, Schwartz ML, Hill RL, McKee PA: Mechanism of anerod anticoagulation. A direct proteolytic effect on fibrin. *J Clin Invest* 51:2841, 1972
15. Alving BM, Evatt BL, Bell WR: Stimulation of fibrinogen synthesis by thrombin in rabbits with anerod-induced afibrinogenemia. *Am J Physiol* 233:H562, 1977
16. Bell WR: Defibrinogenation with arvin in thrombotic disorders, in Sherry S and Scriabine A (eds): *Platelets and Thrombosis*. Baltimore, University Park Press, 1974, p 273
17. Gaffney PJ, Curtis AD: A collaborative study of a proposed international standard for tissue plasminogen activator (t-PA). *Thromb Haemostas* 53:134, 1985
18. Colucci M, Paramo JA, Stassen JM, Collen D: Influence of the fast-acting inhibitor on *in vivo* thrombolysis induced by tissue-type plasminogen activator in rabbits. *J Clin Invest* 78:138, 1986
19. Castellino FJ, Powell JR: Human plasminogen. *Methods Enzymol* 80:365, 1980
20. Wiman B, Mellbring G, Ranby M: Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. *Clin Chim Acta* 127:279, 1983
21. Chmielewska J, Ranby M, Wiman B: Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. *Thromb Res* 31:427, 1983
22. Granelli-Piperno A, Reich E: A study of proteases and protease-inhibitor complexes in biological fluids. *J Exp Med* 148:223, 1978
23. Puchtler H, Sweat F, Doss N: A one-hour phosphotungstic acid hematoxylin stain. *Tech Bull Reg Med Technol* 33:144, 1963
24. Morrison DC, Ulevitch RJ: The effects of bacterial endotoxins on host mediation systems. *Am J Pathol* 93:527, 1978
25. Muller-Berghaus G, Lohmann E: The role of complement in

endotoxin-induced disseminated intravascular coagulation: Studies in congenitally C₆-deficient rabbits. Br J Haematol 28:403, 1974

26. Muller-Berghaus G, Hocke M: Production of the generalized Schwartzman reaction in rabbits by anecrod ("Arvin") infusion and endotoxin injection. Br J Haematol 25:111, 1973

27. Muller-Berghaus G, Eckhardt T: The role of granulocytes in the activation of intravascular coagulation and the precipitation of soluble fibrin by endotoxin. Blood 45:631, 1975

28. Szczepanski M, Lucer C: Soluble fibrin monomer complexes

and fibrinolytic activity in kidney during the generalized Schwartzman reaction in rabbit. Thromb Res 6:399, 1975

29. Bergstein JM, Michael AF Jr: Renal cortical fibrinolytic activity in the rabbit following one or two doses of endotoxin. Thromb Diathes Haemorrh 29:27, 1973

30. Sakata Y, Aoki N: Cross-linking of α_2 -plasmin inhibitor to fibrin by fibrin stabilizing factor. J Clin Invest 65:290, 1980

31. Wardle EN: Fibrin in renal disease: Functional considerations. Clin Nephrol 2:85, 1974

Accession For	
NTIS GRA&I	☒
DTIC TAB	☐
Unannounced	☐
Justification	
By	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	20

